Published in J Cancer Sci Ther on June 30, 2014
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res (2009) 2.50
Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med (2000) 2.40
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care (2012) 2.32
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer (2011) 2.30
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer (2009) 2.08
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Impact of comorbidity on lung cancer survival. Int J Cancer (2003) 1.95
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (2010) 1.85
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer (2011) 1.70
Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol (2011) 1.61
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol (2004) 1.51
Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. Ann Thorac Surg (2012) 1.46
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
Metformin and cancer therapy. Curr Opin Oncol (2012) 1.27
Diabetes is not associated with longer survival in patients with lung cancer. Arch Intern Med (2001) 1.25
Metformin and neoplasia: implications and indications. Pharmacol Ther (2011) 1.20
Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer (2011) 1.15
The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer (2012) 1.08
DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer (2006) 1.01
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J (2012) 1.01
Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med (2007) 0.94
Revisions to the TNM staging of non-small cell lung cancer: rationale, clinicoradiologic implications, and persistent limitations. Radiographics (2011) 0.92
Patients with diabetes-induced microangiopathy show a reduced frequency of carcinomas. In Vivo (1999) 0.84
Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer (2011) 0.81
Is VAMLA/TEMLA the new standard of preresection staging of non-small cell lung cancer? J Thorac Cardiovasc Surg (2012) 2.05